Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel (ALCOOTAX)
This study is currently recruiting participants.
Verified July 2011 by Institut Curie
Information provided by (Responsible Party):
First received: October 6, 2011
Last updated: October 10, 2011
Last verified: July 2011
The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Institut Curie:
Primary Outcome Measures:
- Evaluation of plasma alcohol [ Time Frame: One year ] [ Designated as safety issue: No ]Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||October 2012|
|Estimated Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
Intervention Details:Detailed Description:
Other: blood sampling
Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
In this study, there is no experimental treatment, or experimental care.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01448759
|Contact: MARAL Sylvie, UGEC Leaderemail@example.com|
|Paris, France, 75005|
|Contact: MARAL Sylvie, UGEC Leader 0156245630 firstname.lastname@example.org|
Sponsors and Collaborators
|Principal Investigator:||LE TOURNEAU Christophe, MD||Institut Curie|